Yes, that is exactly how I think this has to be understood. BMSN responds to the FDA-questions in Q3. In order to be able (allowed) to start trials with Hemaxellerate in Q4 (as written in the PR), the FDA-approval has to take place somewhere in between theses two dates, IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.